MX2022004806A - Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). - Google Patents

Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).

Info

Publication number
MX2022004806A
MX2022004806A MX2022004806A MX2022004806A MX2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A MX 2022004806 A MX2022004806 A MX 2022004806A
Authority
MX
Mexico
Prior art keywords
vit
nice
anemia
compositions
methods
Prior art date
Application number
MX2022004806A
Other languages
English (en)
Spanish (es)
Inventor
Vania Manolova
Naja Nyffenegger
Franz Dr Dürrenberger
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of MX2022004806A publication Critical patent/MX2022004806A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MX2022004806A 2019-10-22 2020-10-22 Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). MX2022004806A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
EP20163777 2020-03-17
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (1)

Publication Number Publication Date
MX2022004806A true MX2022004806A (es) 2022-05-16

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004806A MX2022004806A (es) 2019-10-22 2020-10-22 Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).

Country Status (11)

Country Link
US (1) US20220274973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048262A1 (cg-RX-API-DMAC7.html)
JP (1) JP7594004B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086563A (cg-RX-API-DMAC7.html)
CN (1) CN114765955B (cg-RX-API-DMAC7.html)
AU (1) AU2020369137A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154524A1 (cg-RX-API-DMAC7.html)
IL (1) IL291137A (cg-RX-API-DMAC7.html)
MX (1) MX2022004806A (cg-RX-API-DMAC7.html)
WO (1) WO2021078889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN121511085A (zh) 2023-06-26 2026-02-10 威佛(国际)股份公司 用于遗传性血色素沉着病(hh)的治疗的膜铁转运蛋白抑制剂
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis
WO2026120152A1 (en) 2024-12-06 2026-06-11 Vifor (International) Ag Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Also Published As

Publication number Publication date
US20220274973A1 (en) 2022-09-01
AU2020369137A1 (en) 2022-04-07
BR112022007616A2 (pt) 2022-07-12
JP2023500060A (ja) 2023-01-04
IL291137A (en) 2022-05-01
KR20220086563A (ko) 2022-06-23
JP7594004B2 (ja) 2024-12-03
CN114765955A (zh) 2022-07-19
CA3154524A1 (en) 2021-04-21
EP4048262A1 (en) 2022-08-31
WO2021078889A1 (en) 2021-04-29
CN114765955B (zh) 2025-06-24

Similar Documents

Publication Publication Date Title
MX2024008551A (es) Terapias de combinacion.
EA202190630A1 (ru) Способы комбинированной терапии
PH12022550469A1 (en) Kras g12d inhibitors
MX2022000711A (es) Inhibidores de parp1.
EA202090419A1 (ru) Селективные ингибиторы инфламмасомы nlrp3
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX394961B (es) Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
NZ708593A (en) Novel pyrazole derivative
BR112022007616A2 (pt) Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763)
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
JOP20180036A1 (ar) أملاح لمثبطات فروبورتين جديدة
EA201791576A1 (ru) Ингибитор jak
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
TR201904158T4 (tr) Osteoartrit tedavisi için adamts inhibitörleri olarak 5-[(piperazin-1-il)-3-okso-propil]-imidazolidin-2,4-dion türevleri.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы